Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
| dc.contributor.author | Attard, G | |
| dc.contributor.author | Sydes, M | |
| dc.contributor.author | Mason, M | |
| dc.contributor.author | Clarke, Noel W | |
| dc.contributor.author | Aebersold, D | |
| dc.contributor.author | de Bono, J | |
| dc.contributor.author | Dearnaley, D | |
| dc.contributor.author | Parker, C | |
| dc.contributor.author | Ritchie, A | |
| dc.contributor.author | Russell, J | |
| dc.contributor.author | Thalmann, G | |
| dc.contributor.author | Cassoly, E | |
| dc.contributor.author | Millman, R | |
| dc.contributor.author | Matheson, D | |
| dc.contributor.author | Schiavone, F | |
| dc.contributor.author | Spears, M | |
| dc.contributor.author | Parmar, M | |
| dc.contributor.author | James, N | |
| dc.date.accessioned | 2014-09-04T09:06:12Z | |
| dc.date.available | 2014-09-04T09:06:12Z | |
| dc.date.issued | 2014-06-27 | |
| dc.identifier.citation | Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. 2014: Eur Urol | en |
| dc.identifier.issn | 1873-7560 | |
| dc.identifier.pmid | 24985962 | |
| dc.identifier.doi | 10.1016/j.eururo.2014.05.038 | |
| dc.identifier.uri | http://hdl.handle.net/10541/325844 | |
| dc.description.abstract | There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to European urology | en |
| dc.title | Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. | en |
| dc.type | Article | en |
| dc.contributor.department | The Institute of Cancer Research, London, UK | en |
| dc.identifier.journal | European Urology | en |
| html.description.abstract | There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. |